

**CATALYST PHARMACEUTICAL PARTNERS, INC.**

355 Alhambra Circle  
Suite 1500  
Coral Gables, Florida 33134  
(305) 529-2522

February 18, 2014

**VIA EDGAR AND E-MAIL**

Securities and Exchange Commission  
100 F. Street, N.E.  
Washington, D.C. 20549

Re: Catalyst Pharmaceutical Partners, Inc.  
Amendment No. 1 to  
Registration Statement on Form S-3  
File No. 333-193699

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Catalyst Pharmaceutical Partners, Inc. (the "Company") hereby requests that the effective date of the above-referenced Amendment No. 1 to Form S-3 Registration Statement be accelerated to 10:00 a.m., Washington, D.C. time, on Thursday, February 20, 2014, or as soon thereafter as is practicable.

In making its request, the Company acknowledges that:

- (i) should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, that act will not foreclose the Commission from taking any action with respect to the filing;
- (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosures in the Registration Statement.
- (iii) the Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States; and

(iv) the Company is aware of its obligations under the Act, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement.

Please call Philip Schwartz (at 954-468-2455) at Akerman LLP as soon as the Registration Statement has been declared effective.

Thank you for your courtesy and cooperation.

Very Truly Yours,

/s/ Alicia Grande

---

Alicia Grande

Vice President, Treasurer and CFO

Cc: Jeffrey P. Riedler (SEC)  
Christine De Rosa